GlaxoSmithKline's (GSK) Buy Rating Reiterated at Liberum Capital


's stock had its "buy" rating reaffirmed by investment analysts at Liberum Capital in a research report issued on Thursday, November 9th. They currently have a GBX 1,760 price objective on the stock.



from Biotech News